News|Articles|February 13, 2025
Executive Summary: Addressing Regulatory Requirements for CRISPR sgRNA Purity with Orthogonal Chromatography
Author(s)Agilent
The increasing demand for high-purity, regulatory-compliant guide RNA (gRNA) manufacturing in the CRISPR gene editing market underscores the need for advanced production capabilities.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
FDA Priority Review of Subcutaneous Lecanemab Signals Shift in Alzheimer’s Treatment Delivery
2
FDA Fast Tracks Innovent’s Trispecific Antibody for Multiple Myeloma
3
HanchorBio–WuXi Biologics Partnership Targets Fusion Protein Development Challenges
4
GSK’s Arexvy Gains EU Approval for Adults Aged 18 Years and Older
5